Chien‐Chin Lin

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

Uwe Platzbecker, Matteo Giovanni Della Porta, Valeria Santini et al. · The Lancet · 2023 · 164 citations · Full text

Medicine, Hematology, Pharmacology +14

Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome

Hsin‐An Hou, Cheng‐Hong Tsai, Chien‐Chin Lin et al. · Blood Cancer Journal · 2018 · 94 citations · Full text

Medicine, Genetics, Molecular Genetics +16

<i>IDH</i> mutations are closely associated with mutations of <i>DNMT3A</i>, <i>ASXL1</i> and <i>SRSF2</i> in patients with myelodysplastic syndromes and are stable during disease evolution

Chien‐Chin Lin, Hsin‐An Hou, Wen‐Chien Chou et al. · American Journal of Hematology · 2013 · 83 citations · Full text

Medicine, Genetics, Hematology +9

Splicing factor mutations predict poor prognosis in patients with <i>de novo</i> acute myeloid leukemia

Hsin‐An Hou, Chieh‐Yu Liu, Yuan‐Yeh Kuo et al. · Oncotarget · 2016 · 81 citations · Full text

Medicine, Hematology, Oncology +13

Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax

Yuwen Wang, Cheng‐Hong Tsai, Chien‐Chin Lin et al. · Annals of Hematology · 2020 · 73 citations

Medicine, Hematology, Oncology +14